Transcription of NSSG Chemotherapy Protocol
{{id}} {{{paragraph}}}
Example: confidence
NSSG Chemotherapy Protocol
Myeloid group This is a controlled document and therefore must not be changed Imatinib Authorised by Myeloid lead Prof Adam Mead Oct 2019 Version Page 1 of 6 IMATINIB (CML) INDICATION Licensed / NICE indication Standard-dose Imatinib is recommended as first-line treatment of adults with chronic phase Ph+ chronic myeloid leukaemia (CML) [NICE TA70, TA426] Imatinib is recommended for the treatment of patients with Ph+ CML who initially present in the accelerated phase or with blast crisis. Additionally, Imatinib is recommended for patients who present in the chronic phase and then progress to the accelerated phase or blast crisis if they have not received Imatinib previously.
Dose adjustment for Haematological Toxicity Indication Counts Modification Chronic phase CML (400mg) ANC < 1.0 x 109/L and/or Plt < 50 x 109/L 1. Stop Imatinib until ANC ≥ 1.5 x 10 9/L and Plt ≥ 75 x 10/L 2. Resume treatment at previous dose 3. Recurrence of ANC < 1.0 x 10 9/L and/or Plt < 50 x 10 /L,
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: